Mr. Murad Novruzov | Immunotherapy | Pharmaceutical Excellence Award

Ronin Institute | Azerbaijan

Mr. Murad Novruzov is an independent researcher whose work spans the intersecting frontiers of immunology, cancer biology, experimental oncology, neurology, and functional neuroscience. His research focuses on building theoretical and preclinical frameworks that advance the understanding of complex diseases, particularly late-stage cancer and neurological disorders. His scientific interests include cancer immunotherapy, tumor microenvironment dynamics, bacteriotherapy, cytokine-based treatments, T-cell engineering, oncolytic bacterial systems, and enzymatic tumor disruption. Complementing his work in oncology, he also explores neuropathy rehabilitation, peripheral nerve injury mechanisms, neuroregeneration, and the development of non-surgical motor recovery protocols.Over the course of his multidisciplinary journey, Mr. Novruzov has contributed to several organizations across biomedical research, information technology, healthcare analytics, and academic innovation. He is affiliated with the Ronin Institute and serves as a researcher within Health & Science Initiatives, where he is involved in shaping novel biomedical concepts and translational research directions. His long-standing involvement in Murad Novruzov Biomedical Research reflects his commitment to independent scientific inquiry, allowing him to develop unconventional yet scientifically grounded strategies for personalized oncology and neurofunctional rehabilitation.Beyond laboratory and theoretical research, Mr. Novruzov possesses extensive experience in IT systems integration, analytical model development, and large-scale data processing. His leadership role at Minihomme highlights his ability to merge technical and scientific expertise, while his work in major healthcare institutions demonstrates his proficiency in big data analytics, clinical data interpretation, and medical informatics. His contributions extend to academia and scientific administration, where he has supported analysis system development and participated in international scientific relations at prominent institutions.Mr. Novruzov maintains a strong presence in global scientific networks through platforms such as SciProfiles and ORCID, allowing him to share his evolving body of work with the wider research community. His interdisciplinary perspective—uniting oncology, immunology, neurology, computational modeling, and IT—positions him as a versatile thinker dedicated to advancing next-generation biomedical solutions. Driven by curiosity and innovation, he continues to develop theoretical protocols aimed at transforming future approaches in personalized medicine, cancer therapy, and neuroregenerative science.

Profile: Orcid

Featured Publications

Novruzov, M., Mammadova, M., & Shiraliyeva, U. Hypothetical Mechanisms of Immune Response Activation Under Profound Suppression. Zenodo. DOI: 10.5281/ZENODO.16740757.

Novruzov, M., Mammadova, M., & Shiraliyeva, U. Hypothetical Mechanisms of Immune Response Activation Under Profound Suppression (Preprint). Preprint Server. DOI: 10.2196/preprints.86151.

Novruzov, M., Mammadova, M., Raval, K., & Shiraliyeva, U. Second Breath: Systems-Level Model of Localized Immune Cascade Programming in Desmoplastic Tumors (In Silico-Validated, Literature-Anchored) (Preprint). Preprint Server. DOI: 10.2196/preprints.85933.

Novruzov, M., & Shiraliyeva, U. Malignant Tumors: Therapeutic Modalities, Mechanisms, Step-by-Step Application, Toxicities and Clinical Interactions. Zenodo. DOI: 10.5281/ZENODO.17219649.

Dr. Denise Faustman | Immunotherapy | Best Researcher Award

Associate Professor of Medicine at Harvard Medical School | United States

Dr. Denise Faustman is a physician-scientist recognized for her pioneering work in immunology, autoimmunity, and type 1 diabetes research. She serves as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Her career bridges clinical medicine, molecular biology, and translational research, with a focus on advancing novel therapies for autoimmune diseases. Dr. Faustman has significantly contributed to understanding immune tolerance, vaccine-based interventions, and the role of BCG vaccination in autoimmune modulation. She is widely respected for her leadership, scientific advisory roles, and commitment to women’s health and immunological innovation.

Publication Profile

Scopus

Education

Dr. Denise Faustman earned a B.S. in Zoology and Chemistry from the University of Michigan, followed by an M.D. and Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine in St. Louis. She completed her postdoctoral training in transplantation immunology at Washington University before pursuing clinical training in internal medicine and endocrinology at Massachusetts General Hospital and Harvard Medical School. Her combined training in medicine, molecular biology, and immunology has uniquely positioned her to integrate clinical insights with advanced laboratory science, fueling her translational research on autoimmunity, immunotherapy, and novel strategies for the treatment of chronic diseases.

Experience

Dr. Denise Faustman has built a distinguished career at Harvard Medical School and Massachusetts General Hospital, where she directs the Immunobiology Laboratory. Her academic roles span from Instructor to Associate Professor of Medicine, combined with leadership in clinical and translational immunology. She has served on numerous national and international scientific committees, including advisory roles at the FDA, NIH, NAS, and Institute of Medicine. As a physician-scientist, she bridges patient care with laboratory innovation, advancing novel treatments for autoimmune diseases. She has also provided scientific leadership for biotech companies, foundations, and research councils, shaping biomedical policy, discovery, and translational impact.

Awards and Honors

Dr. Denise Faustman contributions have been recognized through prestigious appointments and leadership roles. She has served as Chair and Board Member of the Society for Women’s Health Research, Advisory Committee Member for the FDA, and Chair of national immunology and autoimmunity symposia. She has been elected to scientific advisory boards for biotechnology companies and foundations worldwide, including Sjögren’s Syndrome Foundation and Farallone Therapeutics. Her expertise has been sought by NASA, NIH, and the Department of Defense for defining priorities in immunology, vaccine safety, and women’s health. These roles reflect her influence, innovation, and leadership in advancing immunological and biomedical sciences.

Research Focus

Dr. Denise Faustman research centers on autoimmunity, immune regulation, and translational immunotherapy. Her laboratory is internationally recognized for pioneering studies on immune tolerance and the use of BCG vaccine as a potential therapy for type 1 diabetes. She investigates mechanisms of T cell regulation, biomarkers for autoimmune progression, and pathways of immune modulation to translate discoveries into clinical applications. Her work bridges fundamental immunology with patient-centered research, aiming to develop safe, effective, and durable treatments for chronic autoimmune diseases. By integrating laboratory science, clinical trials, and translational medicine, Dr. Faustman is shaping innovative therapeutic strategies with global health impact.

Publication Top Notes

The spleen assumes a major role in blood glucose regulation in type 1 diabetes patients treated with BCG

Late in the US pandemic, multi-dose BCG vaccines protect against COVID-19 and infectious diseases

Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Association of BCG Vaccine Treatment with Death and Dementia in Patients with Non-Muscle-Invasive Bladder Cancer

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells

Letter to the Editor Regarding “The Non-Significant Benefit of BCG Vaccination for the Treatment of Iranian Patients with Type 1 Diabetes up to 48 Weeks: A Controversial Result”

The benefits of clustering in TNF receptor superfamily signaling

Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies

BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes

Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes

Murad Novruzov | Immunotherapy | Pharmaceutical Excellence Award

Mr. Murad Novruzov | Immunotherapy | Pharmaceutical Excellence Award

Featured Publications

Denise Faustman | Immunotherapy | Best Researcher Award